What question did this study set out to answer?

To evaluate the effectiveness of a high-throughput drug sensitivity assay for predicting treatment responses in relapsed/refractory multiple myeloma.

P06 | From Bench to Bedside: Drug Sensitivity Profiling to Optimize Therapy in Relapsed Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Authors

High-throughput drug sensitivity profiling predicts responses in relapsed multiple myeloma, indicating potential for precision treatment.

To evaluate the effectiveness of a high-throughput drug sensitivity assay for predicting treatment responses in relapsed/refractory multiple myeloma.
Evaluated a novel drug sensitivity assay in patients with relapsed/refractory multiple myeloma.
Tumor cells isolated from CD138+ plasma cells and tested against various drug panels.
Drug response assessed through IC50, area under the curve (AUC), and drug sensitivity scores (DSS).
Receiver operating characteristic (ROC) analysis performed to evaluate DSS performance.
40 patients enrolled, with mean prior lines of therapy of 5.
Overall response rate after subsequent treatments was 51.4%.
Median progression-free survival was 5.7 months.
Top drug responses in testing included bortezomib, carfilzomib, and marizomib.

Cassano et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark